Molecular basis of human immunodeficiency virus drug resistance: an update.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Antiviral Research

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.antiviral.2009.07.006PMID 19616029
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Potent inhibitors of HIV-1 integrase display a two-step, slow-binding inhibition mechanism which is absent in a drug-resistant T66I/M154I mutant.

  2009cited by this paper
• Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography

  2009cited by this paper
• Impact of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors on Evolution of Resistance to the Maturation Inhibitor Bevirimat (PA-457)

  2009cited by this paper
• Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41

  2009cited by this paper
• Mechanisms Associated with HIV-1 Resistance to Acyclovir by the V75I Mutation in Reverse Transcriptase*

  2009cited by this paper
• Susceptibility of Human Immunodeficiency Virus Type 1 to the Maturation Inhibitor Bevirimat Is Modulated by Baseline Polymorphisms in Gag Spacer Peptide 1

  2009cited by this paper
• Catalytically-active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs

  2009cited by this paper
• Replicative Capacity Differences of Thymidine Analog Resistance Mutations in Subtype B and C Human Immunodeficiency Virus Type 1

  2009cited by this paper
• Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies

  2009cited by this paper
• Design of Peptide-based Inhibitors for Human Immunodeficiency Virus Type 1 Strains Resistant to T-20*

  2009cited by this paper
• Gag Mutations Strongly Contribute to HIV-1 Resistance to Protease Inhibitors in Highly Drug-Experienced Patients besides Compensating for Fitness Loss

  2009cited by this paper
• Emerging pharmacology: inhibitors of human immunodeficiency virus integration.

  2009cited by this paper
• Inhibitors of viral entry.

  2009cited by this paper
• A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors

  2009cited by this paper
• Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors

  2009cited by this paper
• Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency

  2009cited by this paper
• HR-2 Mutations in Human Immunodeficiency Virus Type 1 gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical Resistance to Enfuvirtide

  2009cited by this paper
• Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics.

  2009cited by this paper
• Non-Cleavage Site Gag Mutations in Amprenavir-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) Predispose HIV-1 to Rapid Acquisition of Amprenavir Resistance but Delay Development of Resistance to Other Protease Inhibitors

  2009cited by this paper
• Sifuvirtide, a potent HIV fusion inhibitor peptide.

  2009cited by this paper
• Inhibition of HIV‐2 Protease by HIV‐1 Protease Inhibitors in Clinical Use

  2008cited by this paper
• HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision

  2008cited by this paper
• The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain

  2008cited by this paper
• Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro

  2008cited by this paper
• Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.

  2008cited by this paper
• Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.

  2008cited by this paper
• Gln151 of HIV-1 Reverse Transcriptase Acts as a Steric Gate Towards Clinically Relevant Acyclic Phosphonate Nucleotide Analogues

  2008cited by this paper
• Preclinical Evaluation of GS-9160, a Novel Inhibitor of Human Immunodeficiency Virus Type 1 Integrase

  2008cited by this paper
• Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance.

  2008cited by this paper
• Ninety-Nine Is Not Enough: Molecular Characterization of Inhibitor-Resistant Human Immunodeficiency Virus Type 1 Protease Mutants with Insertions in the Flap Region

  2008cited by this paper
• Mutations in Human Immunodeficiency Virus Type 1 Integrase Confer Resistance to the Naphthyridine L-870,810 and Cross-Resistance to the Clinical Trial Drug GS-9137

  2008cited by this paper
• Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors.

  2008cited by this paper
• Recent progress in antiretrovirals--lessons from resistance.

  2008cited by this paper
• The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation

  2008cited by this paper
• Raltegravir treatment response in an HIV-2 infected patient: a case report.

  2008cited by this paper
• Potential limitation of CCR5 antagonists: drug resistance more often linked to CXCR4-utilizing than to CCR5-utilizing HIV-1

  2008cited by this paper
• Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains

  2008cited by this paper
• Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region.

  2008cited by this paper
• Bevirimat: A Novel Maturation Inhibitor for the Treatment of HIV-1 Infection

  2008cited by this paper
• Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.

  2008cited by this paper
• Importance of Protease Cleavage Sites within and Flanking Human Immunodeficiency Virus Type 1 Transframe Protein p6* for Spatiotemporal Regulation of Protease Activation

  2008cited by this paper
• Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants.

  2008cited by this paper
• SC29EK, a Peptide Fusion Inhibitor with Enhanced α-Helicity, Inhibits Replication of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide

  2008cited by this paper
• In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject

  2008cited by this paper
• The Antiherpetic Drug Acyclovir Inhibits HIV Replication and Selects the V75I Reverse Transcriptase Multidrug Resistance Mutation*

  2008cited by this paper
• Gln151 of HIV-1 reverse transcriptase acts as a steric gate towards clinically relevant acyclic phosphonate nucleotide analogues.

  2008cited by this paper
• Peptide inhibitors of HIV-1 egress.

  2008cited by this paper
• Connection Domain Mutations N348I and A360V in HIV-1 Reverse Transcriptase Enhance Resistance to 3′-Azido-3′-deoxythymidine through Both RNase H-dependent and -independent Mechanisms

  2008cited by this paper
• Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors.

  2008cited by this paper
• Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1

  2008cited by this paper
• Impact of the enfuvirtide resistance mutation N43D and the associated baseline polymorphism E137K on peptide sensitivity and six-helix bundle structure.

  2008cited by this paper
• Visualizing transient events in amino-terminal autoprocessing of HIV-1 protease

  2008cited by this paper
• Clinical Implications of Resistance to Antiretrovirals: New Resistance Technologies and Interpretations

  2008cited by this paper
• Tipranavir-Ritonavir Genotypic Resistance Score in Protease Inhibitor-Experienced Patients

  2008cited by this paper
• Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

  2008cited by this paper
• HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.

  2008cited by this paper
• HIV-1 protease inhibitors: effects on HIV-2 replication and resistance.

  2008cited by this paper
• Mechanistic Studies of a T20-Dependent Human Immunodeficiency Virus Type 1 Variant

  2008cited by this paper
• A Mg2+‐induced conformational switch rendering a competent DNA polymerase catalytic complex

  2008cited by this paper
• Selection of T1249-Resistant Human Immunodeficiency Virus Type 1 Variants

  2008cited by this paper
• Update of the Drug Resistance Mutations in HIV-1.

  2008cited by this paper
• Novel targets for HIV therapy.

  2008cited by this paper
• Integrase and integration: biochemical activities of HIV-1 integrase

  2008cited by this paper
• Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase.

  2008cited by this paper
• Design and Evaluation of Sifuvirtide, a Novel HIV-1 Fusion Inhibitor*

  2008cited by this paper
• Integrase, LEDGF/p75 and HIV replication

  2008cited by this paper
• Virologic Response to Lopinavir-Ritonavir-Based Antiretroviral Regimens in a Multicenter International Clinical Cohort: Comparison of Genotypic Interpretation Scores

  2008cited by this paper
• Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues.

  2008cited by this paper
• High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations

  2008cited by this paper
• HIV-1 integrase inhibitors: update and perspectives.

  2008cited by this paper
• HIV-1 protease: structure, dynamics, and inhibition.

  2007cited by this paper
• Relative Fitness and Replication Capacity of a Multinucleoside Analogue-Resistant Clinical Human Immunodeficiency Virus Type 1 Isolate with a Deletion of Codon 69 in the Reverse Transcriptase Coding Region

  2007cited by this paper
• The epidemiology of HIV coreceptor tropism.

  2007cited by this paper
• Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K)

  2007cited by this paper
• Human Immunodeficiency Virus Types 1 and 2 Exhibit Comparable Sensitivities to Zidovudine and Other Nucleoside Analog Inhibitors In Vitro

  2007cited by this paper
• Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine.

  2007cited by this paper
• N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine and Nevirapine Resistance

  2007cited by this paper
• AIDS virus envelope spike structure.

  2007cited by this paper
• Effects of the Translocation Status of Human Immunodeficiency Virus Type 1 Reverse Transcriptase on the Efficiency of Excision of Tenofovir

  2007cited by this paper
• A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance Mechanism

  2007cited by this paper
• Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097.

  2007cited by this paper
• Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance

  2007cited by this paper
• 3'-Azido-3'-deoxythymidine-(5')-tetraphospho-(5')-adenosine, the product of ATP-mediated excision of chain-terminating AZTMP, is a potent chain-terminating substrate for HIV-1 reverse transcriptase.

  2007cited by this paper
• Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.

  2007cited by this paper
• Caught in the Act: the 1.5 A resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate.

  2007cited by this paper
• Mutations in Human Immunodeficiency Virus Type 1 RNase H Primer Grip Enhance 3′-Azido-3′-Deoxythymidine Resistance

  2007cited by this paper
• Evolution of Genotypic and Phenotypic Resistance during Chronic Treatment with the Fusion Inhibitor T-1249

  2007cited by this paper
• Mortality after myocardial infarction in HIV-infected patients who have initiated HAART

  2007cited by this paper
• Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137)

  2007cited by this paper
• Insertions in the beta3-beta4 loop of reverse transcriptase of human immunodeficiency virus type 1 and their mechanism of action, influence on drug susceptibility and viral replication capacity.

  2007cited by this paper
• Selection of Mutations in the Connection and RNase H Domains of Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Increase Resistance to 3′-Azido-3′-Dideoxythymidine

  2007cited by this paper
• HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

  2007cited by this paper
• The Pyrophosphate Analogue Foscarnet Traps the Pre-translocational State of HIV-1 Reverse Transcriptase in a Brownian Ratchet Model of Polymerase Translocation*

  2007cited by this paper
• Probing nonnucleoside inhibitor‐induced active‐site distortion in HIV‐1 reverse transcriptase by transient kinetic analyses

  2007cited by this paper
• HIV entry inhibitors.

  2007cited by this paper
• HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry.

  2007cited by this paper
• Insertions and deletions in HIV-1 reverse transcriptase: consequences for drug resistance and viral fitness.

  2006cited by this paper
• Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen

  2006cited by this paper
• Human Immunodeficiency Virus Type 1 Resistance to the Small Molecule Maturation Inhibitor 3-O-(3′,3′-Dimethylsuccinyl)-Betulinic Acid Is Conferred by a Variety of Single Amino Acid Substitutions at the CA-SP1 Cleavage Site in Gag

  2006cited by this paper
• Drug evaluation: bevirimat--HIV Gag protein and viral maturation inhibitor.

  2006cited by this paper

• Microbiota in drug resistance.

  2025cites this paper
• An Enzymatic Route to the Synthesis of Tricyclic Fused Hexahydrofuranofuran P2-Ligand for a Series of Highly Potent HIV-1 Protease Inhibitors.

  2024cites this paper
• Development in the Inhibition of Dengue Proteases as Drug Targets.

  2023cites this paper
• Discovery of novel sulfonamide substituted indolylarylsulfones as potent HIV-1 inhibitors with better safety profiles

  2023cites this paper
• Structural Modifications Introduced by NS2B Cofactor Binding to the NS3 Protease of the Kyasanur Forest Disease Virus

  2023cites this paper
• 4-Phenylcoumarin derivatives as new HIV-1 NNRTIs: Design, synthesis, biological activities, and computational studies.

  2023cites this paper
• Prediction and molecular field view of drug resistance in HIV-1 protease mutants

  2022cites this paper
• Beyond darunavir: recent development of next generation HIV-1 protease inhibitors to combat drug resistance.

  2022cites this paper
• Elasticity-Associated Functionality and Inhibition of the HIV Protease.

  2021cites this paper
• Synthesis and biological evaluation of pyrrolidine-functionalized nucleoside analogs

  2021cites this paper
• Parallel molecular mechanisms for enzyme temperature adaptation

  2021cites this paper
• Computational Modeling of the Virucidal Inhibition Mechanism for Broad-Spectrum Antiviral Nanoparticles and HPV16 Capsid Segments.

  2021cites this paper
• Contingency and chance erase necessity in the experimental evolution of ancestral proteins

  2021cites this paper
• Molecular Docking-Based Screening for Novel Inhibitors of the Human Immunodeficiency Virus Type 1 Protease that Effectively Reduce the Viral Replication in Human Cells

  2020cites this paper
• Chance, contingency, and necessity in the experimental evolution of ancestral proteins

  2020cites this paper
• Characterization of resistance to a potent d-peptide HIV entry inhibitor

  2019cites this paper
• The discovery and development of oxalamide and pyrrole small molecule inhibitors of gp120 and HIV entry.

  2019cites this paper
• Serine Protease Inhibitor AEBSF Reduces Dengue Virus Infection via Decreased Cholesterol Synthesis.

  2019cites this paper
• Recent update on anti-dengue drug discovery.

  2019cites this paper
• Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase

  2019cites this paper
• HIV Vaccine

  2018cites this paper
• HIV resistance to raltegravir François Clavel

  2018cites this paper
• High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial

  2018cites this paper
• Laboratory Diagnosis of HIV-1 Infections: State of the Art

  2018cites this paper
• Prediction of HIV Drug Resistance by Combining Sequence and Structural Properties

  2018cites this paper
• Conjugation of phosphonoacetic acid to nucleobase promotes a mechanism-based inhibition

  2018cites this paper
• Use of Capillary Electrophoresis to Study the Binding Interaction of Aptamers with Wild-Type, K103N, and Double Mutant (K103N/Y181C) HIV-1 RT

  2017cites this paper
• Rezistencija virusa ljudske imunodeficijencije tipa 1 na inhibitore integraze

  2017influential citation
• Peptides as Therapeutic Agents for Dengue Virus

  2017cites this paper
• New Antiretrovirals for HIV and Antivirals for HBV

  2017cites this paper
• Distinct Pattern of Thymidine Analogue Mutations with K65R in Patients Failing Tenofovir-Based Antiretroviral Therapy

  2017cites this paper
• Flavivirus NS2B/NS3 Protease: Structure, Function, and Inhibition

  2017cites this paper
• Resolution of Specific Nucleotide Mismatches by Wild-Type and AZT-Resistant Reverse Transcriptases during HIV-1 Replication.

  2016cites this paper
• Computer-Aided Druggability Detector: A Computerized Apparatus for Quickening Drug Discovery Processes

  2016cites this paper
• Improving and validating data-driven genotypic interpretation systems for the selection of antiretroviral therapies

  2016cites this paper
• New developments in flavivirus drug discovery

  2016cites this paper
• Multiscale Systems‐Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV‐1

  2016cites this paper
• Science Journals — AAAS

  2016cites this paper
• Synthesis of HIV-1 capsid protein assembly inhibitor (CAP-1) and its analogues based on a biomass approach.

  2016cites this paper
• Unfolding the HIV-1 reverse transcriptase RNase H domain – how to lose a molecular tug-of-war

  2016cites this paper
• Which Patient Characteristics Among Cocaine Users with HIV Relate to Drug Use and Adherence Outcomes Following a Dual-Focused Intervention?

  2016cites this paper
• Adaptive Evolution of the SIV Envelope Protein During Early SIV Infection

  2016cites this paper
• The impact of antiretroviral therapy used in pregnancy on the health of HIV-positive women

  2016influential citation
• Identification of mutational pathways to tenofovir resistance in subtype C isolates using a Bayesian Network.

  2016cites this paper
• Protein/peptide‐based entry/fusion inhibitors as anti‐HIV therapies: challenges and future direction

  2016cites this paper
• Identification of covalent active site inhibitors of dengue virus protease

  2015cites this paper
• Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands.

  2015cites this paper
• NMR characterization of HIV-1 reverse transcriptase binding to various non-nucleoside reverse transcriptase inhibitors with different activities

  2015cites this paper
• Modelling HIV resistance development under the selective pressure of rare drug combinations

  2015cites this paper
• Subtype-Specific Analysis of the K65R Substitution in HIV-1 That Confers Hypersusceptibility to a Novel Nucleotide-Competing Reverse Transcriptase Inhibitor

  2015cites this paper
• Novel Computerized Approaches to Investigating Pharmacological Activities

  2015influential citation
• Computer-Aided Drug Potency Decoder: A Biomedical/Bioengineering Device for Determining and Distinguishing Drug Efficacies

  2015cites this paper
• Characterizing protease inhibitor failure in HIV-1 subtype C, using ultra deep pyro-sequencing and homology modelling.

  2015influential citation
• Quasispecies Dynamics in Disease Prevention and Control

  2015influential citation
• "Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets.

  2014cites this paper
• Phenotype Inference from Genotype in RNA Viruses

  2014cites this paper
• Serendipitous discovery of 2-((phenylsulfonyl)methyl)-thieno[3,2-d]pyrimidine derivatives as novel HIV-1 replication inhibitors.

  2014cites this paper
• The effects of the W 153 L substitution in HIV reverse transcriptase on viral replication and 1 drug resistance to multiple categories of reverse transcriptase inhibitors 2

  2014cites this paper
• Structure-based design of conformationally flexible reverse transcriptase inhibitors to combat resistant HIV.

  2014cites this paper
• Robust against Drug Resistance HIV-1 Protease Inhibitors Designed To Be Hypothesis: Structural Analysis of Novel Evaluating the Substrate-Envelope

  2014cites this paper
• Biomarkers for tuberculosis in the context of HIV/AIDS in Ethiopia

  2014cites this paper
• Horizontal gene transfer from human host to HIV-1 reverse transcriptase confers drug resistance and partly compensates for replication deficits.

  2014cites this paper
• Mutacije povezane s rezistencijom virusa ljudske imunodeficijencije tipa 1 na antiretrovirusne lijekove

  2014influential citation
• Effects of the W153L Substitution in HIV Reverse Transcriptase on Viral Replication and Drug Resistance to Multiple Categories of Reverse Transcriptase Inhibitors

  2014cites this paper
• Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection.

  2014cites this paper
• Insight into HIV-1 reverse transcriptase–aptamer interaction from molecular dynamics simulations

  2014cites this paper
• Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.

  2014cites this paper
• Prediction of HIV drug resistance from genotype with encoded three-dimensional protein structure

  2014cites this paper
• Inhibitors Rilpivirine and Etravirine Nonnucleoside Reverse Transcriptase Defining Patterns of Resistance to Interactions with the M184I Mutation on HIV-1 Reverse Transcriptase and Their Effect of Mutations at Position E138 in

  2014cites this paper
• Current Perspectives on HIV-1 Antiretroviral Drug Resistance

  2014cites this paper
• HIV Drug Resistant Prediction and Featured Mutants Selection using Machine Learning Approaches

  2014influential citation
• Horizontal gene transfer from human host to HIV-1 reverse transcriptase confers drug resistance and partly compensates for replication de fi cits

  2014cites this paper
• Wikstroelide M potently inhibits HIV replication by targeting reverse transcriptase and integrase nuclear translocation.

  2014cites this paper
• A novel, cell‐free PCR‐based assay for evaluating the inhibitory activity of antiretroviral compounds against HIV reverse transcriptase

  2014cites this paper
• Characterization of amino acids Arg, Ser and Thr at position 70 within HIV-1 reverse transcriptase

  2014cites this paper
• Recent Findings on the Mechanisms Involved in Tenofovir Resistance

  2014cites this paper
• Quantitative assessment of in vivo HIV protease activity using genetically engineered QD‐based FRET probes

  2014cites this paper
• Virologic and immunologic outcome of HAART in Human Immunodeficiency Virus (HIV)-1 infected patients with and without tuberculosis (TB) and latent TB infection (LTBI) in Addis Ababa, Ethiopia

  2013cites this paper
• Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran.

  2013cites this paper
• The Effect of Mutations at Position E 138 in HIV-1 Reverse Transcriptase and their Interactions 1 with the M 184 I Mutation in Defining Patterns of Resistance to the Non-Nucleoside Reverse 2 Transcriptase Inhibitors

  2013cites this paper
• Evolutionary biochemistry: revealing the historical and physical causes of protein properties

  2013cites this paper
• Computational Studies Identifying Entry Inhibitor Scaffolds Targeting the Phe 43 Cavity of HIV‐1 gp120

  2013cites this paper
• Antiviral agents: structural basis of action and rational design.

  2013cites this paper
• Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase and Their Interactions with the M184I Mutation on Defining Patterns of Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Rilpivirine and Etravirine

  2013cites this paper
• Role of the K101E Substitution in HIV-1 Reverse Transcriptase in Resistance to Rilpivirine and Other Nonnucleoside Reverse Transcriptase Inhibitors

  2013cites this paper
• Extracts from Acacia catechu suppress HIV-1 replication by inhibiting the activities of the viral protease and Tat

  2013cites this paper
• The flavivirus protease as a target for drug discovery

  2013cites this paper
• A Novel Dengue Virus Inhibitor, BP13944, Discovered by High-Throughput Screening with Dengue Virus Replicon Cells Selects for Resistance in the Viral NS2B/NS3 Protease

  2013cites this paper
• Identification of benzofurano[3,2-d]pyrimidin-2-ones, a new series of HIV-1 nucleotide-competing reverse transcriptase inhibitors.

  2013cites this paper
• INTERGENERATIONAL PHENOTYPIC MIXING IN VIRAL EVOLUTION

  2013influential citation
• Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (Stribild®): A Review of Its Use in the Management of HIV-1 Infection in Adults

  2013cites this paper
• Structure and Physics of Viruses

  2013influential citation
• Roles of the K 101 E Substitution in HIV-1 Reverse Transcriptase in Resistance to 1 Rilpivirine and other Non-Nucleoside Reverse Transcriptase Inhibitors 2 3

  2013influential citation
• Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments.

  2013cites this paper
• Dengue virus and West Nile virus protease inhibitors

  2013cites this paper
• HIV Reverse Transcriptase Fidelity, Clade Diversity, and Acquisition of Drug Resistance

  2013cites this paper
• Design of the anti-HIV protease inhibitor darunavir

  2013cites this paper
• RNAi as Antiviral Therapy: The HIV-1 Case

  2013cites this paper
• Evolução da resistência in vivo aos inibidores da transcriptase reversa em mães multíparas infectadas pelo vírus da Imunodeficiênca Humana tipo 1 que cumpriram regimes terapêuticos para prevenção da transmissão do vírus aos seus filhos

  2013cites this paper
• Role of RNase H Activity in NRTI/NNRTI Drug Resistance

  2013cites this paper